ReviewImmunological reviews2017
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Review in Immunological reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions.International journal of molecular sciences · 2024Review
- Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.The clinical respiratory journal · 2024Article
- Immune-checkpoint inhibitors for glioblastoma: what have we learned?Arquivos de neuro-psiquiatria · 2022Review
- P2YMolecules (Basel, Switzerland) · 2021Review
- Immune checkpoint: The novel target for antitumor therapy.Genes & diseases · 2021Review
- Review
- Article
- GARP as an Immune Regulatory Molecule in the Tumor Microenvironment of Glioblastoma Multiforme.International journal of molecular sciences · 2019Article
- Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.CNS neuroscience & therapeutics · 2019Article
- CD48 is a key molecule of immunomodulation affecting prognosis in glioma.OncoTargets and therapy · 2019Article
- Modeling phenotypes of malignant gliomas.Cancer science · 2018Review
- Introduction to checkpoint inhibitors and cancer immunotherapy.Immunological reviews · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The introduction of immunotherapy with checkpoint receptor blockade has changed the treatment of advanced cancers, at times inducing prolonged remission. Nevertheless, the success rate of the approach is variable across patients and different tumor types, and treatment is often accompanied by severe immune-related side effects, suggesting the importance of co-inhibitory pathway for both prevention of autoimmunity and failure of tumor rejection. A better understanding of how to uncouple anti-tumor activity from loss of self-tolerance is necessary to increase the therapeutic efficacy of checkpoint immunotherapy. In this review, we describe basic concepts of T-cell exhaustion that occur in cancer, highlighting the role of co-inhibitory receptors in contributing to this process while preventing immunopathology. By providing an overview of the current therapeutic success and immune-related burden of secondary effects of checkpoint immunotherapy, we illustrate the "double-edged sword" related to interference with immune-regulatory pathways. Finally, since achieving tumor rejection while preserving self-tolerance is particularly important for the central nervous system, we analyze the case for checkpoint immunotherapy in glioblastoma, the most common adult brain tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.